Orphan Trial leads to First Therapeutic for the Treatment for aTTP

Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).